Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia - Wikidata - awgldk - TriplyDB

Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia

Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia

http://www.wikidata.org/entity/Q36179100

about

Biomarkers of Aging: From Function to Molecular Biology Clinical Screening Tools for Sarcopenia and Its Management Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment Biomarkers for physical frailty and sarcopenia: state of the science and future developments Effects of Three Types of Exercise Interventions on Healthy Old Adults' Gait Speed: A Systematic Review and Meta-Analysis Insights into muscle degeneration from heritable inclusion body myopathies Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia Essential amino acid supplementation in patients following total knee arthroplasty Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men Quantitative proton MR techniques for measuring fat Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults.Impact of poor muscle strength on clinical and service outcomes of older people during both acute illness and after recovery Efforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention.Muscle wasting: an overview of recent developments in basic research.Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.Moving on up: the Journal of Cachexia, Sarcopenia and Muscle.Pre-hospital dietary intake correlates with muscle mass at the time of fracture in older hip-fractured patients Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014.Genetics of hand grip strength in mid to late life.Sarcopenia-related parameters and incident disability in older persons: results from the "invecchiare in Chianti" study Finding good biomarkers for sarcopenia.From muscle wasting to sarcopenia and myopenia: update 2012 The potential of classic and specific bioelectrical impedance vector analysis for the assessment of sarcopenia and sarcopenic obesity.Functional impact of sarcopenia in respiratory muscles.Diaphragm muscle sarcopenia in aging mice Impact of physical function impairment and multimorbidity on mortality among community-living older persons with sarcopaenia: results from the ilSIRENTE prospective cohort study Effect of resistance training with different frequencies and detraining on muscular strength and oxidative stress biomarkers in older women.Predicting sarcopenia from functional measures among community-dwelling older adults.Procollagen type III N-terminal peptide (P3NP) and lean mass: a cross-sectional study.Isotopic decay of urinary or plasma 3-methylhistidine as a potential biomarker of pathologic skeletal muscle loss.Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms.Availability and use of dual energy X-ray absorptiometry (DXA) and bio-impedance analysis (BIA) for the evaluation of sarcopenia by Belgian and Latin American geriatricians.Muscle quality in aging: a multi-dimensional approach to muscle functioning with applications for treatment.Bone is Not Alone: the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease.Aspects of physical medicine and rehabilitation in the treatment of deconditioned patients in the acute care setting: the role of skeletal muscle.Functional Status Modifies the Association of Blood Pressure with Death in Elders: Health and Retirement Study.Muscle wasting in ageing and chronic illness.Pathogenesis and Management of Sarcopenia.Biomarkers for physical frailty and sarcopenia.

P2860

Q26748324-2D999F91-A940-4C44-A710-D902239FF23E Q26766380-987B75AB-3A1E-48EF-A214-1297974DB415 Q26775254-D27E2171-4EAD-4883-97B8-8F78E1DEE24C Q26775328-009CBCDD-9778-49CE-A611-424897CCB9E0 Q26796729-E53D3A24-BA06-4BF6-9F3D-2280CA93CAF0 Q26851967-02C17990-B800-4756-B3F0-F7C3D2189BD8 Q27022354-1529C105-CD63-412B-9681-45991024C3C9 Q28069408-64AD389E-8DE5-4F44-AB4F-C4CEB8807BFE Q29543859-0D9DD0D0-0BC0-4171-A124-D23EAB6ABBE7 Q30557326-6C0040D9-660F-4B5A-A3CE-A38BE410B1C7 Q30677112-C06AF15C-AE24-4B81-BADE-4F0A316ED8DD Q33741109-904184B6-5F90-422B-8ADE-9D03CCB25F0F Q33776475-4E0DF3C4-E863-4447-84F5-B9F33DD60683 Q34156932-7B1F02D1-4C22-4B3C-BE4C-B9587C319299 Q34156942-D1C256E3-08B1-4AEB-9250-8F2A584BC73C Q34334313-D3F3B7B3-5D7E-49A5-8C87-57510A1FF027 Q34495485-D3EF1F10-4912-4D8D-9A1D-7724380C9CE8 Q34537893-1F1C73B6-036A-4760-BDAF-A22CF69DB946 Q34591010-E22E1007-C2B7-45F0-A444-66D7F7F83DB0 Q35032987-845223E0-BA27-4540-A8A9-DF38313E480B Q35221405-4A94AA23-F56B-4F82-8B55-23E14349A319 Q36179111-A3411765-2A2F-4910-B05E-14BA9B2CB1FE Q36421054-9317585F-4DAC-40D3-9C8D-A12A556D33B3 Q36486946-F28FDEE8-FD75-472E-BE57-9FC432A184CC Q36818574-A8990A48-24D8-4541-AAE2-C2E3161F126B Q37112562-99408F55-E805-48A5-AECE-DEDEC8AC7948 Q37134141-932C94EC-28BB-46E7-8517-DE312DC84F25 Q37219341-786C7501-F4F0-4DE7-9D5E-3D0E2F559B06 Q37219510-724203F8-5113-4264-B314-04F8E3603532 Q37310302-96C91BE7-8C16-4E4A-A0E0-2757549671B6 Q37635905-F7EBD081-CEB6-4DB2-9484-6988A55CCC11 Q38064396-2835B32E-8A83-44F4-8F44-F06E756C7245 Q38268458-7792E05A-EA93-434D-AF47-FACEC512FDC6 Q38345471-34A93530-92BC-4EFB-9752-04DB77B45C73 Q38359416-A43D526C-A860-4572-889E-98FADF3C6003 Q38694058-B1E6CCFD-C15F-4EBB-BCB9-EBAA2421B4A9 Q38901358-17866309-18BF-49E2-8242-8D7CAA9AB7E1 Q39001205-F17F1340-8625-473B-A1EE-E5718623DC11 Q39019596-349415B6-BDBD-4F6B-A80B-1824153F7E56 Q39117124-FCB0F97B-80DD-4912-9CA3-65FED445084F

P2860

Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia

http://www.wikidata.org/entity/Q36179100

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Biomarkers of sarcopenia in cl ...... al Working Group on Sarcopenia

@ast

Biomarkers of sarcopenia in cl ...... al Working Group on Sarcopenia

@en

type

label

Biomarkers of sarcopenia in cl ...... al Working Group on Sarcopenia

@ast

Biomarkers of sarcopenia in cl ...... al Working Group on Sarcopenia

@en

prefLabel

Biomarkers of sarcopenia in cl ...... al Working Group on Sarcopenia

@ast

Biomarkers of sarcopenia in cl ...... al Working Group on Sarcopenia

@en

P1433

Q36179100-FCDBA27A-624B-4F02-871D-781C0F9CB2ED

P1476

Q36179100-4A27EFCF-2500-4564-ACCF-F7EA42144228

P2093

Q36179100-3BDA8DF5-2ADD-48C2-A251-01465E07B51E

Q36179100-40CBB781-C8F0-45BF-8D0A-59322698C21E

Q36179100-613E380C-0009-4ABD-9BAA-7552E2E29F1A

Q36179100-65783800-6AD7-4A86-B3C7-7A6B9AD86B71

Q36179100-70B67853-37D4-4492-B847-0688B67917D6

Q36179100-70E7D245-6E88-49DD-B47B-2B6E733E47D4

Q36179100-8348431A-5D51-4557-B53A-66579F5CBA1D

Q36179100-87F91146-4877-4FD5-844B-0B941BE12C20

Q36179100-A915B360-21EA-4F65-ABE7-F9408BB5E2E6

Q36179100-AAD29B3A-28CC-4509-B23D-26BA1DF30AC2

P2860

Q36179100-0191D24E-4BE4-4F37-B471-D05817704B13

Q36179100-01CD583F-DE21-47AB-8AA5-97D0370A4FFF

Q36179100-0227613B-1CEA-40B8-8A8D-0023A417A89A

Q36179100-062E1B93-9E63-423F-9343-EEDFD3CBDDBF

Q36179100-064FB36A-7BD8-414D-A8BE-47BA70985DD5

Q36179100-09B92C4C-205A-4941-B7A4-5876D7221846

Q36179100-0B26B051-3F15-40BA-9CCB-EBA2E8A7A458

Q36179100-0C6D1C0B-913A-4C87-9D43-7431AD954BEA

Q36179100-0D4357D5-2CE5-41BE-BC3E-5EB705B25356

Q36179100-0E47C360-BF38-480A-8AAE-A7D8214D9FB5

P2888

Q36179100-504120CD-3614-4265-B2B1-D8BE4BD7CF33

P304

Q36179100-FE396B51-8AAC-4DB0-9BC9-9C9402EF256E

P31

Q36179100-1AB22F33-4E0F-4D9B-B152-35685BB47D25

Q36179100-d230a34e-100a-4249-b842-6538e27b0287

P356

Q36179100-1132A91D-9A18-4B6D-8D81-357D83C28FEB

P433

Q36179100-A88A5398-D4A1-4341-B46E-A820CC35831E

P478

Q36179100-B6FE05A1-017F-4809-9E7B-937A963B01E1

P50

Q36179100-13E564C4-89C6-467C-B319-9562766FF06D

Q36179100-41E09B40-2BF3-4FEC-A9E7-ED711C741B86

Q36179100-44F14710-4793-4CDF-8261-F6FCEEE2CEE9

Q36179100-AA434890-D0B3-4D51-9775-0B3268CA423D

P577

Q36179100-633A6FD4-CA2C-4AE8-A117-6BFE26030977

P5875

Q36179100-716B69A3-4DFA-47BE-A3CF-189398A32164

P698

Q36179100-AA81B335-05C4-452C-B7BF-F7F4D77B274E

P921

Q36179100-2E9F2528-3BD8-4444-ABE1-F3E67936D45E

P932

Q36179100-06C994CC-B29D-4296-8970-B5F5F7EF0336

P356

S13539-012-0078-2

P1433

Journal of Cachexia, Sarcopenia and Muscle

P1476

Biomarkers of sarcopenia in cl ...... al Working Group on Sarcopenia

@en

P2093

Bret Goodpaster

http://www.w3.org/2001/XMLSchema#string

Christine M'rini

http://www.w3.org/2001/XMLSchema#string

Cornell C Sieber

http://www.w3.org/2001/XMLSchema#string

Didier Laurent

http://www.w3.org/2001/XMLSchema#string

Gabor A van Kan

http://www.w3.org/2001/XMLSchema#string

International Working Group on Sarcopenia

http://www.w3.org/2001/XMLSchema#string

J Willem Vrijbloed

http://www.w3.org/2001/XMLSchema#string

Jesse M Cedarbaum

http://www.w3.org/2001/XMLSchema#string

John E Morley

http://www.w3.org/2001/XMLSchema#string

Marc Hellerstein

http://www.w3.org/2001/XMLSchema#string

P2860

Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People

FRAX and the assessment of fracture probability in men and women from the UK

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women

Oxidative stress and severe walking disability among older women

Epidemiology of sarcopenia among the elderly in New Mexico

Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics"

Electrical impedance myography: Background, current state, and future directions

Impaired voluntary neuromuscular activation limits muscle power in mobility-limited older adults.

Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study.

P2888

s13539-012-0078-2

P304

181-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13539-012-0078-2

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Stefan D. Anker

Ronenn Roubenoff

P577

2012-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230620212

http://www.w3.org/2001/XMLSchema#string

P698

22865205

http://www.w3.org/2001/XMLSchema#string

P921

P932

3424187

http://www.w3.org/2001/XMLSchema#string